A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients

Current Medical Research and Opinion
M SzelachowskaJ Jopdska

Abstract

Fifteen out-patients with type I diabetes mellitus and microalbuminuria (mean +/- SEM: 95.4 +/- 13.9 micrograms/min), were administered the glycosaminoglycan sulodexide, with the aim of investigating its influence on the rate of albumin excretion. Sulodexide was given intramuscularly in a dose of 600 lipoproteinlipase releasing units/day for three weeks. Albumin excretion was measured before dosing, at weekly intervals during dosing and also during the subsequent follow-up period of six weeks. Sulodexide yielded a clear-cut and statistically significant lowering of albumin excretion after the first week of treatment (from 95.4 +/- 13.9 micrograms/min to 53.6 +/- 11.1 micrograms/min; p = 0.0055); albumin excretion was further decreased after three weeks of treatment (26.5 +/- 6.05 micrograms/min; p = 0.0007) and was maintained during the follow-up period, at the end of which the mean value was still significantly lower than at baseline (39.6 +/- 10.3 micrograms/min; p = 0.01). Sulodexide short-term administration did not influence the routine haematological, haematochemical and coagulative tests performed contemporaneously. Patients' compliance with treatment was very good and no adverse events were reported.

References

Apr 11, 1990·JAMA : the Journal of the American Medical Association·J V SelbyJ Showstack
Oct 1, 1984·The Journal of Clinical Investigation·S M MauerF C Goetz
Jul 1, 1995·Diabetes/metabolism Reviews·A Kofoed-Enevoldsen
Jun 10, 1993·The New England Journal of Medicine·D M Nathan

❮ Previous
Next ❯

Citations

Oct 29, 2011·Journal of the American Society of Nephrology : JASN·David K PackhamUNKNOWN Collaborative Study Group
Jan 1, 2010·International Journal of Nephrology and Renovascular Disease·Antonio V GaddiGiovanni Gambaro
Aug 2, 2006·Treatments in Endocrinology·Cataldo Abaterusso, Giovanni Gambaro
Oct 3, 2007·Glycoconjugate Journal·Tessa J WijnhovenToin H van Kuppevelt
Apr 19, 2005·Expert Opinion on Investigational Drugs·Kei FukamiJosephine M Forbes
May 20, 2014·Expert Opinion on Emerging Drugs·Sergio StefoniMaria Laura Angelini
Jul 25, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Tessa J M WijnhovenToin H van Kuppevelt
Feb 1, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Gary C W Chan, Sydney C W Tang
Mar 15, 2013·Clinica Chimica Acta; International Journal of Clinical Chemistry·Rafael N MorescoGuilherme V Bochi
May 31, 2011·Yonsei Medical Journal·Kitae BangKook-Hwan Oh
Jan 28, 2021·Advances in Therapy·Angelo A BignaminiJiří Matuška
Jun 1, 2002·Journal of the American Society of Nephrology : JASN·Giovanni GambaroGaetano Crepaldi
Feb 9, 2000·Journal of the American Society of Nephrology : JASN·Giovanni Gambaro, Fokko J VAN DER Woude
Aug 30, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Edmund J LewisUNKNOWN Collaborative Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.